OZEM
Roundhill Glp-1 & Weight Loss ETF
Price Chart
Latest Quote
$32.37
-0.30 (-0.92%)
Current Price
| Previous Close | $32.67 |
| Open | $32.14 |
| Day High | $32.50 |
| Day Low | $31.79 |
| Volume | 14,462 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.27% |
| Net Assets | $54.08M |
| Expense Ratio | 0.59% |
| Category | Health |
| Fund Family | Roundhill Investments |
| Net Asset Value | $32.88 |
| Premium/Discount | -1.56% |
| Quarterly Dividend Yield | 1.27% |
| P/E Ratio | 13.90 |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $32.49 |
| SMA50 | $31.55 |
| SMA200 | $32.01 |
| RSI | 54.50 |
| ATR | 0.6301 |
| Rel Volume | 0.47 |
Performance History
| Week | -2.27% |
| Month | +6.18% |
| Quarter | +1.23% |
| 6 Months | -10.16% |
| YTD | -5.74% |
| Year | +25.57% |
| 10 Years | +29.36% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $32.37 | 14,500 |
| 2026-07-16 | $32.84 | 13,000 |
| 2026-07-15 | $32.90 | 5,600 |
| 2026-07-14 | $32.33 | 50,700 |
| 2026-07-13 | $32.75 | 31,700 |
| 2026-07-10 | $33.12 | 33,400 |
| 2026-07-09 | $33.40 | 13,400 |
| 2026-07-08 | $33.54 | 30,400 |
| 2026-07-07 | $34.06 | 31,000 |
| 2026-07-06 | $33.75 | 25,600 |
| 2026-07-02 | $33.55 | 52,200 |
| 2026-07-01 | $32.39 | 92,500 |
| 2026-06-30 | $32.54 | 75,800 |
| 2026-06-29 | $32.74 | 37,000 |
| 2026-06-26 | $31.85 | 18,900 |
| 2026-06-25 | $31.40 | 11,600 |
| 2026-06-24 | $31.59 | 32,600 |
| 2026-06-23 | $31.29 | 11,700 |
| 2026-06-22 | $31.01 | 23,400 |
| 2026-06-18 | $30.39 | 12,700 |
About Roundhill Glp-1 & Weight Loss ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
📰 Latest News
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Zacks • 2026-07-01T12:13:00Z
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
MarketBeat • 2026-06-20T12:45:00Z
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks • 2026-06-10T16:00:00Z
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Zacks • 2026-05-19T18:27:00Z
Scoring 2 Million Prescriptions, Novo’s GLP-1 Pill Crushes Expectations
The Daily Upside • 2026-05-07T04:01:00Z
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
MarketBeat • 2026-04-17T15:20:00Z
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Zacks • 2026-03-23T15:27:00Z
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Zacks • 2026-02-04T14:30:00Z
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
MarketBeat • 2026-01-19T20:23:00Z
2 under-the-radar ETFs retail investors should jump on
Yahoo Finance Video • 2026-01-07T11:00:38Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.